| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT05640999 Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer… |
Trial sites expanded: 114 -> 118 locations |
| 2026-08-12 | NCT01396408 A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours |
date change Completion pushed: 2026-06-30 -> 2026-12-31 |
| 2026-08-12 | NCT07390435 Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials |
Trial sites expanded: 8 -> 11 locations |
| 2026-08-12 | NCT06043427 Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal… |
date change Primary completion pushed: 2026-06-30 -> 2026-12-31 |
| 2026-08-12 | NCT06043427 Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal… |
date change Completion pushed: 2026-12-31 -> 2027-07-31 |
| 2026-08-12 | NCT02436707 Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell… |
date change Primary completion pushed: 2026-06-30 -> 2026-12-31 |
| 2026-08-01 | NCT04093167 Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer |
Enrollment closed, study ongoing |
| 2026-08-01 | NCT04093167 Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer |
Enrollment reduced: 230 -> 53 participants |
| 2026-07-21 | NCT05470010 Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer… |
overall status: Recruiting → Active, Not Recruiting |
| 2026-07-21 | NCT05470010 Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer… |
Enrollment reduced: 345 -> 300 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06235697 | Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment | Prostate Cancer | Recruiting |
| NCT06439225 | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma | Unresectable/Metastatic Melanoma | Recruiting |
| NCT03550391 | Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy… | Brain Metastases | Recruiting |
| NCT05451004 | SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized… | Oropharyngeal Cancer | Recruiting |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older… | Multiple Myeloma | Recruiting |
| NCT06205485 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | Rectal Cancer | Recruiting |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… | Prostate Cancer (Adenocarcinoma) | Recruiting |
| NCT06641791 | Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in… | Advanced Head and Neck Cancer | Recruiting |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Non-small Cell Lung Cancer | Recruiting |
| NCT06391242 | Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful… | Cancer Metastatic | Recruiting |
| NCT02273375 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04650581 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive… | Breast Cancer | Active, Not Recruiting |
| NCT03488693 | Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Breast Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT04093167 | Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05180097 | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for… | Hodgkin Lymphoma | Recruiting |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT05998642 | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed… | Non-hodgkin Lymphoma | Recruiting |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2… | Breast Cancer | Recruiting |
| NCT06623461 | LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint… | Melanoma | Recruiting |
| NCT03847649 | A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior… | Cancer | Recruiting |
| NCT04918186 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | Ovarian Cancer | Recruiting |
| NCT05640999 | Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer… | Endometrial Cancer | Recruiting |
| NCT06043427 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal… | Gastroesophageal Adenocarcinoma | Recruiting |
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable… | Hepatocellular Carcinoma | Recruiting |